U.S. Markets close in 4 hrs 38 mins

Antares Pharma, Inc. (ATRS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.19+0.02 (+0.79%)
As of 11:20AM EDT. Market open.
People also watch
  • Put Copaxone in it! Stockvadar-foresees

    Without referencing glatimar acetate, Antares
    has quietly developed (patent granted):

    1. A pre-filled syringe glass cartridge

    2. with a shorter penetration needle (close to 100% zero leakage)

    3. capable of injecting 1 ml in 2 seconds (100-300 psi)

    4. which as a needle-assisted jet injector overcomes
    a patient's skin thickness, various factors

    5. that unlike Mumford's does not leak back on
    the skin.

    Just CLICK IT baby!!!

  • New position for 'Quality Engineer' in Minneapolis just listed on home base. There are now two openings listed. This is good to see.
  • Piper Jeffray reiterates buy on Antares with pt of $4. I know $4 is low but still better than nothing
  • I had supersight surgery 33 hours ago. They replace the lenses in your eyes with artificial ones. Gets you back to 20/20 vision. I've been varying specs since I was 10. Ah how to make a long story short. I Like What I SEE😳
  • If Connor Mcgregor can manifest a fight with Floyd Mayweather then we can manifest a buy-out for $20+, above most peoples wildest imagination, if we keep believing that it will be so and let the magic of the things we have yet to fully understand play out. The vessel is FRED @ APPLE, the bad seeds are old TEVA and MYLAN and the magic is to balance those opposing forces to ATRS goodness by manifesting greatness and glory followed by the fairest weather fan.
  • Pre-Market News ALERT: Teva appears on track for AB rated generic Epipen, Stockvadar-summarizes

    Investors learned on Tuesday that unless an
    overdue update appears on USPTO, Teva has
    abandoned the 'branded' path for the MORE
    FAVORABLE AB RATED path for Epipen. As
    Mylan's generic expired in mid-June, the FDA's
    been working with Teva. Now it appears investors
    have been 'tipped off' in advance of a formal
    PR unless something dramatic happens on the
    USPTO website.

    Meanwhile, Copaxone is back in conversation
    though connecting the dots is yet completed. In
    other news rumors are spinning about a BO, the
    plans for BIGSHOT, and whether Antares will
    announce its calculated quiet season as a lot
    of possibilities are on the table.

    As of this morning, it remains that Teva must be
    on the path to AB RATED approval for Epipen,
    risk assumed.

    We anticipate more volatility in trading as a
    sudden drop in short positions was reported
    last evening. We expect recent highs to be
    tested as MMs, HFs, insiders have their own
    channels into the FDA. News also appears to
    confirm that Exenatide's approval is equally
    close which would make Q3 a banner quarter.

  • As noted, they are just tid-bits....but they add up.......

    1) it looks like ATRS has plans for big growth, and training their employees for it........Antares chipped in $49,437, to train their employees......


    Hennepin Technical College and Antares Pharma, Inc., Plymouth – $49,437

    Thirty-five employees will participate in courses based on occupational need. The training will expand manufacturing processes, increase productivity and accuracy, and implement standardization across all product lines.

    2) An oldie but goodie worth a read, loko was waiting for SV to post, since SV is such a Great researcher.....

    Antares helped fund the study...it will extend the use of exenatide....do a search on Eric Klien....


    3) EU authorized new marketing terms for exenatide....it can't hurt....


    Now the debbie downers have something to down........losers.....

    Now get that GoFund for loko's kayak.....and loko could post s lot more....

  • Alright SV, and fellow real investors....

    loko can not handle it anymore......

    and needs to get it out before popping...

    dig into these four numbers.....

    then get those happy fingers going on one possible new combo.........

    1) Recently granted patent...... 9707264
    2) Recently filed updated patent application ... US 20170196930 .....make note of the additional claims......especially #41....
    3) Tademark.... 87244791 .......SV already made note of it.....
    4) Patent application....WO2016172048......SV already made note of it.....

    Put them all together, and what do you get....

    Woooo Weeeee.......

    ATRS is going to rock......3XW
  • Geez, my hair has more volume...
  • Could be TIP-OFF that GENERIC EPIPEN is COMING, Stockvadar-follows-up

    We consulted with resident expert L-daug
    regarding the observation that either Teva
    has let Rescuject & Jr trademark's expire
    including Jecteva, or it could be the website
    has not been updated--if so it is way out of

    In response the King of DD, L-daug responded:
    "Due to different filing dates, it looks like some
    of the jectva TMs missed the deadline as well,
    the others are close to being abandon. Will need
    to check for updates, because as noted, maybe
    it is just a technicality." And he then added: "One
    could only guess Teva gave up on the idea of
    going the Branded route and will just have a generic
    Epipen...Or worst, no epipen...."

    Bravo! And here's why Antares investors this
    likely it is not "no epipen" (Well let's hope not),
    but MORE LIKELY it is an early sign that Teva
    is being granted the AB rated generic Epipen!!!

    We believe Teva is aware that is going to gain
    Epipen AB rated approval, thus no need for the
    trademark names. Put another way, investors
    might see this post for what it could be: an early
    TIP ahead of a PR that Teva has been granted

    This post could stir a market response once
    the clear logic is understood. PS - L-daug also
    acknowledged that something could be in the
    works for "BIGSHOT".

    We believe Antares' pps is going higher.

  • NEWS ALERT: Why the PPS could EXPLODE UP, Stockvadar-notes

    Here's what's happening. The USPTO that regularly
    updates its website shows that there has been no
    trademark extension filed for Rescuject & Jr. We
    provide Rescuject's data for examination. As you'll
    see, it is WAY OVERDUE as Teva was suppose to
    file by July 5 and 19, 2017. They have not. Jecteva & Jr.
    are the same story.

    Rescuject serial #s
    86916805 Jan. 19, 2017 ITU Extension Approval Jan. 19, 2017 ITU Unit Action
    86916804 Jan. 05, 2017 ITU Extension Approval Jan. 05, 2017 ITU Unit Action
    86916803 Jan. 05, 2017 ITU Extension Approval Jan. 05, 2017 ITU Unit Action
    86916799 Jan. 05, 2017 ITU Extension Approval Jan. 05, 2017 ITU Unit Action

    Therefore, if Teva let's these trademarks fall to the
    wayside, it means they apparently are not going after
    a branded epinephrine, and actually, that makes sense.
    Sense because, it means they are on the path with the
    FDA to be granted the AB rated epinephrine generic; the
    very goal that give Antares a bonus upon approval.

    Since mid-June, the generic runway has been clear for
    Teva. Apparently Teva must have a high degree of
    confidence that the AB green-light is coming, and now
    probably, very soon. The reason why the pps could explode
    up in advance of the PR is because MMs, HFs, insiders, etc
    all have that unspoken-magical ability to know when to buy.
    If our observation is correct, this trademark revelation is
    giving the market an advanced tip on public information.
    After all, why would Teva let its trademarks expire unless
    they had a high degree of confidence that approval was
    coming? After all, if they didn't get AB rating, then they
    could go the branded product route. So it appears that
    Teva has exposed what's about to show up in a PR, and
    it also explains why Antares has been very very quiet.

    It is also obvious that once this information was made
    public the pps began a slow climb, almost as if seeking
    to remain below the radar. Finally, it's a given it's always a
    gift to buy in advance of positive news, but that is always
    up to the investor's own discretion as any of this is not
    without risk. If the USPTO suddenly updates, though every
    day it becomes less likely, then...

    Ourselves, we think the probability of gaining AB rating has
    gone way up.

  • Short interest down over last two week reporting period
    6/30/17 8,834,048
    7/14/17 7,404,340

    That is a considerable decrease over a two week period. Very good sign and could be an indicator of approaching news ?
  • Why have Teva NOT RENEWED Rescuject Trademark? Stockvadar-asks-L-daug

    Trademarks once approved must be renewed by
    extension until a company markets the product.
    That renewal is every six months which Teva acted
    upon for Rescuject and Jr. back in January 2017.
    The thing is, the extension period has passed and
    unless the government needs to update its files,
    there is no record of renewal extensions. For example,
    Rescuject was renewal-extended Jan 5 & 19. 2017... point
    is THESE ARE OVER-DUE. Why? Perhaps the wise,
    knowledgeable, ambitious, kind, gentle, clairvoyant
    L-daug can inform investors about this?

    NOW THE BIG NEWS (Yup, tucked inside this post on
    Rescuject). It's a REAL SHAME L-daug didn't post about
    this, we will-- ARE YOU READY?

    Jan 10, 2017 got approval for this Trademark. On July 12
    2017 Antares was granted its first extension. Its name:
    BIGSHOT. The question is, If Antares is ALREADY saying
    that Xyosted will be the "T" name, then what's BIGSHOT for?
    It seems like Antares has something cooking and here again
    we turn to L-daug to enlighten all of us. Of course, we all know
    Teva has a product requiring a BIGSHOT, but why is Antares
    moving this trademark forward? What's the project?

    We have more, but seeing how the pps went up we'll
    hold off.

  • Two big buys in AH over the past week. Somebody is in stealth accumulation mode. A big FILL will set the MMs into overdrive to skim shares by dropping the SP and taking out YOUR stop(s).

    Right now, the August CRL Desert can be navigated and or obsoleted by the company via the following;

    - new pen approval in EURO with an impact statement. IE- with this approval we see a ramp in X$s/qtr over the next X qtrs.

    - deliver rev. of $15M/qtr. This is roughly B-E. B-E is important as it enables a BO offer.

    - update on any positive FDA info. IE-- they might have passed the manufacturing visit or the label is a GO, any or all of these say: XYO is Approved, just waiting on the final notification.

    - This is the biggie: IF the company is going to self market XYO--then we need to hear solid updates about their intended market share goals, their plans to capture that share, their projected lives potentially insured/covered for XYO pending FDA approval on Dec. 1st, the start of pen production date( i.e. Oct.21) and their first IN MARKET date for the sales force.

    --- IF the above is NOT stated firmly, then we know that discussions are underway for a BO

    I am not asking them to lie or to divulge secrets, rather that they support the SP which is undervalued by 2-2.75 times their near term potential. I want to see $8-9/sh by FDA approval. And a clear commitment to greatness by aggressively pursuing the TESTOS NEEDLE market and to some extend the TESTOS PATCH market.
  • Earnings from SUMA should be almost flat.
    Q4 16 Market share 19%, Booked in Q1 17
    Q1 17 Market share 21%, Booked in Q2 17
    Q2 17 showing a large pickup as mentioned by the company in one of the last presentations.
    No miracles from OTREXUP but anyway all that is not to important.
    It's all about the next 9-12 months. Approvals Galore
  • Update: AB Generic EpiPen ONLY Option? Stockvadar-breaks

    Branded names remain grossly overdue at this point
    on the USPTO website, again suggesting that Teva
    is on the homestretch of announcing the AB rated
    generic for EpiPen.

    Trading is yet to respond to this good news. And
    Antares is now setting the record for remaining silent
    suggesting something very positive is in the works.
    Still, investors are feeling frustrated as the market
    goes higher. Pay-day could be very soon, and
    sudden. Nerves of steel on Thursday!

  • Does anyone know when Antares is set to release their quarterly. Can't find anything.
  • Pre-market massive activity
    2 Shares at $ 3.20 (08:59:50 AM)
  • I see a possibility for near term news based on the appearance of the recent drop. Many of you are familiar with the mid June drop of ADMP on no news. The very next day their syringe EPI was approved and the stock popped up well over a dollar per share. I am hopeful that good news is imminent...
  • Injectables for HIV could this be the next revolution.
    They provide slow and steady delivery of meds .
    ATRS injector , why not.